Tetsuo Hasegawa, Masaru Ishii ≪Immunology and Cell Biology≫ Researchers split the “AtoM” in search of a treatment for rheumatoid arthritis
Journal: Nature Immunology
Researchers at Osaka University discover a new type of bone-dissolving osteoclast that contributes to rheumatoid arthritis
Arthritis is a common chronic disease in which joints become inflamed, leading to stiffness and pain that can often be debilitating. Rheumatoid arthritis (RA) is an autoimmune form of the disease, arising when immune cells attack the tissue that lines the joints. There is a need for new treatment options, as current therapies only alleviate symptoms or, at best, slow the disease. Now, in a study published in Nature Immunology, researchers at Osaka University have discovered a previously unknown type of RA-causing cell within arthritic joints that could someday be a target for new treatments.
There are two major cellular culprits that contribute to RA. The first are immune cells, which release inflammatory chemicals around the tissue of affected joints. The second are osteoclasts, specialized cells that secrete acids and enzymes to break down bone. Osteoclasts normally help to remodel healthy bone, but in RA their bone-dissolving ability goes into overdrive and damages joints.
“The disease-modifying anti-rheumatic drugs available today predominantly act against the inflammatory response of immune cells,” says Masaru Ishii, professor at Osaka University Graduate School of Medicine and corresponding author of the study. “Therapies targeting osteoclasts are limited, largely because we don’t know enough about the osteoclasts involved in RA. We were interested in understanding whether these cells are somehow different from the osteoclasts involved in normal physiological processes.”
Osteoclasts are elusive, residing along the surface of bone under layers of cartilage and tissue. This makes them difficult to isolate in the lab, even with tractable models like mice. To collect the cells, the research group had to develop a surgical technique that allowed them to extract osteoclasts from the femurs of arthritic mice. With osteoclasts securely in hand, they were then able to gather new insights into RA.
“We tracked precisely how arthritis-inducing osteoclasts develop from their undifferentiated precursor cells,” explains Tetsuo Hasegawa, lead author of the study. “While normal osteoclasts are derived from stem cells in the bone marrow, we found that osteoclasts involved in RA come from blood-borne precursors. The circulating precursors enter the joint and differentiate into a unique sub-type of osteoclasts, which are larger and have distinct markers that aren’t seen in other osteoclasts.”
The newly discovered cells, dubbed “AtoMs” (Arthritis-associated osteoclastogenic Macrophages), have properties that could be exploitable in the search for new treatments. In one example highlighted by the study, the researchers found that AtoMs have high levels of a protein (called FoxM1) known to make cells invade nearby tissue. They speculated that by getting rid of this hallmark protein—splitting the AtoM, if you will—they could perhaps quell its arthritic tendencies. This is indeed what they found: when FoxM1 was chemically or genetically disrupted in AtoMs, arthritic mice showed reduced bone destructions in their joints.
“Our findings suggest that osteoclasts involved in RA have distinct properties that make them amenable to therapeutic targeting,” says co-author Masaru Ishii. “While there is still a lot to learn about this class of cells, we believe the discovery could open the door to new avenues of treatment.”
The article, “Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1” was published in Nature Immunology at DOI: 10.1038/s41590-019-0526-7
Summary: Rheumatoid arthritis is a chronic, disabling disease in which the joints become swollen and painfully inflamed. Current treatments can only reduce symptoms or slow the disease course. Researchers at Osaka University discovered a new type of osteoclast (bone-dissolving cell) involved in the disease, called AtoMs. The cell type has unique properties that can potentially be targeted by new treatments for rheumatoid arthritis.
Primary Keyword: Biology
Additional Keywords: Cell Biology, Developmental Biology, Genetics, Molecular Biology
Title:“Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1”
Journal: Nature Immunology
Authors: Tetsuo Hasegawa, Junichi Kikuta, Takao Sudo, Yoshinobu Matsuura, Takahiro Matsui, Szandor Simmons, Kosuke Ebina, Makoto Hirao, Daisuke Okuzaki, Yuichi Yoshida, Atsushi Hirao, Vladimir V. Kalinichenko, Kunihiro Yamaoka, Tsutomu Takeuchi, and Masaru Ishii
Funded by: Japan Society for the Promotion of Science, Japan Science and Technology Agency
About Osaka University
Osaka University was founded in 1931 as one of the seven imperial universities of Japan and now has expanded to one of Japan’s leading comprehensive universities. The University has now embarked on open research revolution from a position as Japan’s most innovative university and among the most innovative institutions in the world according to Reuters 2015 Top 100 Innovative Universities and the Nature Index Innovation 2017. The university’s ability to innovate from the stage of fundamental research through the creation of useful technology with economic impact stems from its broad disciplinary spectrum.